These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38710155)

  • 21. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
    Rech MA; Masic D; Hammond DA
    West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
    Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
    Maragkos GA; Nelton EB; Richter S; Stippler M
    World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin.
    Heath M; Hall B; De Leon J; Gillespie R; Hasara S; Henricks B; Lakshmi M; Watson D; Wilson K
    Am J Emerg Med; 2022 Jul; 57():149-152. PubMed ID: 35580546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight-Based Dosing Versus a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate in Obese Patients Requiring Vitamin K Antagonist Reversal.
    Elsamadisi P; Cepeda MAG; Yankama T; Wong A; Tran Q; Eche IM
    Am J Cardiovasc Drugs; 2021 May; 21(3):355-361. PubMed ID: 33150496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
    Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
    Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probable pulmonary embolism with repeat administration of prothrombin complex concentrate in a factor Xa inhibitor patient.
    King GS; Cottingham LG; Hughes RE; Ratliff PD
    J Clin Pharm Ther; 2018 Dec; 43(6):903-905. PubMed ID: 29885249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
    Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
    J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of modified fixed dose four-factor prothrombin complex concentrate for warfarin reversal.
    Peterson ME; Jaynes MP; Berardi S; Morton C
    J Thromb Thrombolysis; 2024 Jun; 57(5):865-870. PubMed ID: 38581551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemostatic Efficacy and Safety of Weight-Based Versus Fixed-Dose 4F-PCC for Vitamin K Antagonist Reversal.
    Milkovits AE; Sugrue D; Faris J; Schad JL; McAllister KB
    J Pharm Pract; 2024 Jan; ():8971900241228779. PubMed ID: 38241183
    [No Abstract]   [Full Text] [Related]  

  • 32. High-dose versus low-dose 4-factor prothrombin complex concentrate for factor Xa inhibitor reversal in intracranial hemorrhage.
    Davis SD; Chauv S; Hickman AW; Collingridge DS; Kjerengtroen S; Fontaine GV
    Thromb Res; 2021 Dec; 208():112-116. PubMed ID: 34749042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
    Bitonti MT; Rumbarger RL; Absher RK; Curran LM
    J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors.
    Hormese M; Littler A; Doane B; Glowacki N; Khimani A; Vivacqua N; Rudenberg K
    J Thromb Thrombolysis; 2021 Oct; 52(3):828-835. PubMed ID: 33725284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients.
    Whitaker C; McKinney A; Bollig R; Hieb N; Roberts RF; Rowe AS
    J Thromb Thrombolysis; 2022 May; 53(4):861-867. PubMed ID: 34787787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage.
    Dybdahl D; Walliser G; Chance Spalding M; Pershing M; Kincaid M
    Am J Emerg Med; 2019 Oct; 37(10):1907-1911. PubMed ID: 30651183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients.
    Allison TA; Lin PJ; Gass JA; Chong K; Prater SJ; Escobar MA; Hartman HD
    J Intensive Care Med; 2020 Sep; 35(9):903-908. PubMed ID: 30244638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors.
    Pon G; Pelsue B; Reddy ST; Parsha K; Zhang X; Gulbis B; Barreto A; Savitz SI; Escobar M; Allison TA
    Thromb Res; 2023 Sep; 229():46-52. PubMed ID: 37406569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage.
    Cascone AE; Daley MJ; Pan N; Padilla-Tolentino E; Milling TJ
    Pharmacotherapy; 2021 Jun; 41(6):501-507. PubMed ID: 33866591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
    Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
    Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.